Choosing pan-HDAC or selective HDAC inhibitors for anticancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Epigenetics

Background:

• Histone deacetylase (HDAC) dysfunction is implicated in cancer development and progression.
• Aberrant expression of classical HDACs is observed across various cancer types.
• The specific HDACs involved can range from single overactive isozymes to multiple classes.

Purpose of the Study:

• To resolve the ambiguity surrounding the optimal choice between selective and pan-HDAC inhibitors for cancer therapy.
• To provide evidence-based guidance for selecting the most effective HDAC inhibitor regimen.

Main Methods:

• Analysis of HDAC expression patterns in different cancer types.
• Review of existing literature on HDAC inhibitors (HDACi) and their efficacy.
• Correlation of HDAC overexpression profiles with therapeutic responses to HDACi.

Main Results:

• HDAC expression patterns are heterogeneous across different cancers.
• The involvement of HDACs can be specific to certain isozymes or encompass multiple classes.
• A clear link exists between specific HDAC overexpression patterns and the effectiveness of particular HDAC inhibitors.

Conclusions:

• The optimal therapeutic strategy for HDAC inhibitors depends on the specific cancer's HDAC overexpression profile.
• Matching HDAC inhibitor type (selective vs. pan-inhibitor) to the cancer's molecular signature is crucial for effective treatment.
• This approach offers a personalized medicine strategy for HDAC inhibitor-based cancer therapy.